ArticleScientific reports2025
Investigating the biological activities of Sapindus mukorossi seed hydrosol and its potential as a skincare ingredient.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this study was to investigate notable biological activities and medical applications of Sapindus mukorossi (S. mukorossi) seed hydrosol in wound healing. In this study, S. mukorossi hydrosol (SMH) was prepared and tested for antimicrobial, anti-inflammatory, and tissue repair activity. Phytochemical analysis using GC-MS revealed SMH to contain two bioactive components, benzene, 1,3-bis(1,1-dimethylethyl), and 2,4-di-tert-butylphenol (2,4-DTBP). Antibacterial testing showed that SMH powder diluted with water at a ratio of 1:2 (SMH 1:2) reduced S. aureus colony counts by 60% (p < 0.05). In vitro viability assays on CCD-966SK fibroblasts demonstrated enhanced cell survival under serum-free conditions, with SMH 1:2 yielding the most sustained effects. Scratch assays confirmed that SMH 1:2 promoted fibroblast migration and significantly accelerated wound closure at 24 and 48 h (p < 0.05). Anti-inflammatory testing showed that SMH 1:2 reduced LPS-induced NO production in RAW 264.7 cells (p < 0.01). In vivo wound healing in rats indicated that SMH 1:2 improved epithelial recovery, resulting in significantly smaller wound areas compared to control on day 14 (8.25% ± 3.85% vs. 14.04% ± 3.50%, p < 0.05). Histological examination confirmed enhanced re-epithelialization in SMH-treated wounds. These findings indicate that S. mukorossi hydrosol holds promise as both a wound-healing agent and an ingredient for use in skincare product development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.